GrowBlox Sciences, Inc. (GBLX)

logo-2As medical marijuana gains more acceptance, many companies are now participating not only in distributing the product, but also in research and development to improve the production chain. GrowBlox Sciences, Inc is a company that offers solutions for cultivating and processing medical cannabis. Based in Las Vegas, Nevada, this development-stage company develops proprietary technologies that it intends to implement through state-level partners.

A primary technology of GrowBlox Sciences is the GrowBlox Cannabis Grow Chamber. It is an indoor plant-growing chamber with controlled climate and environmental parameters. Another is the InCUBEator Cannabis Propagation Chamber, which is used to ensure consistency in the tissue culture method of cannabis cultivation.

For the extraction of medicinal cannabis compounds, GrowBlox Sciences has ConversionLAB. It uses CO2 to help ensure that the extract is clean. In the final process of drying and curing, the company uses the CureBLOX Cannabis Drying System, which follows a specific algorithm for temperature and humidity. This makes the curing process and the product pathogen-free.

GrowBlox Sciences also presents itself as a leader in processing state and local licenses where there are medical cannabis programs. The company has specialists who cover standard application requests like compliance, security, branding, packaging, and sales plans.

Founded in 2001, GrowBlox Sciences, Inc started out as Flagstick Ventures, Inc. It became the Diabetic Treatment Centers of America, Inc in 2004, then Signature Exploration and Production Corp in 2008. Finally, it changed to GrowBlox Sciences, Inc in April 2014.

The company, valued at USD 22.41 M, currently trades in the OTC markets as GBLX. Its key executives are Craig M. Ellins, CEO and Chairman; Steven W. Weldon, CFO and Chief Accounting Officer; and Dr. Andrea Small-Howard, Chief Science Officer.

Yahoo! Finance: GBLX News

Latest Financial News for GBLX

GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation

LAS VEGAS, Sept. 17, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC.  The stake will be purchased by Wellcana Plus LLC, affiliated through its managers with the group which holds the other 50% of the Louisiana operations.  Expected to close by the end of October 2019, the sale is for $16 million to GB Sciences, $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out.  The actual proceeds realized through the earn out and the timing of those proceeds will depend upon the profitability of the Louisiana operations. The sale will greatly reduce the current and future burn rate of the Company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the US Food and Drug Administration to ensure quality control in the manufacture of pharmaceuticals, dietary supplements and natural health products among other substances, at its Las Vegas, Nevada location.

U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers

GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations

LAS VEGAS , Aug. 28, 2019 /CNW/ -- GB Sciences, Inc. (GBLX) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager, bringing his extensive and nationally-recognized experience streamlining production, improving product quality, and increasing profitability to GBS.

GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists

Education program includes evidence-based review of FDA-registered human clinical trial data supporting the use of cannabis to treat approved medical conditions. LAS VEGAS, Aug. 7, 2019 /PRNewswire/ -- GB Sciences, Inc. (GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU AgCenter, to further educate Louisiana physicians and pharmacists about the new medical cannabis products that the company will launch in coming months.

History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History

BATON ROUGE, La., Aug. 6, 2019 /PRNewswire/ -- GB Sciences Louisiana (GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified patients in the state's nine licensed pharmacies. This is the first time that qualified patients have legal cannabis medicine available under Louisiana law, marking a historic turning point for patients, advocates, and regulators. "This is a watershed moment for our company and the State of Louisiana, reflecting many years of research and development by GB Sciences into the cannabis plant's biopharmaceutical applications," said John Davis, President of GB Sciences Louisiana.